Related Experiment Video
Updated: Jul 4, 2025

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
Published on: April 24, 2020
Identifying and Exploring the Impact Factors for Intraocular Pressure Prediction in Myopic Children with Atropine
Tzu-En Wu1,2, Jun-Wei Chen3, Tzu-Chi Liu4
1Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 11101, Taiwan.
Insights
Topical atropine for myopia control in children is safe when baseline intraocular pressure (IOP) is below 14 mmHg. Higher baseline IOP may increase IOP with atropine treatment, necessitating careful monitoring.
Area of Science:
- Ophthalmology
- Pediatric Medicine
- Artificial Intelligence in Healthcare
Background:
- Topical atropine is a common treatment for childhood myopia, effective in slowing its progression.
- Monitoring intraocular pressure (IOP) is essential for the safe use of atropine.
- Establishing a precise baseline IOP is crucial for clinical safety assessments.
Purpose of the Study:
- To identify the optimal machine learning module for monitoring IOP in children treated with atropine.
- To establish a precise baseline IOP as a clinical safety reference for atropine therapy.
Main Methods:
- Retrospective analysis of data from 1545 eyes of 1171 children undergoing atropine treatment for myopia.
- Utilized a multivariate adaptive regression spline (MARS) model to analyze 19 variables affecting End IOP.
- Key variables included patient demographics, medical history, refractive error, and IOP measurements.
Main Results:
- The MARS model identified age, baseline IOP, End Spherical, and atropine treatment durations as significant factors influencing End IOP.
- Baseline IOP was the most influential factor, with a critical threshold identified at 14 mmHg.
- A positive correlation between atropine use and End IOP was observed when baseline IOP equaled or exceeded 14 mmHg.
Conclusions:
- The MARS model effectively captures nonlinearity in predicting End IOP compared to traditional linear regression.
- Atropine administration may increase IOP in children with a baseline IOP exceeding 14 mmHg.
- Findings provide critical insights for clinicians to optimize atropine therapy and ensure patient safety.
Purpose:
The treatment of childhood myopia often involves the use of topical atropine, which has been demonstrated to be effective in decelerating the progression of myopia. It is crucial to monitor intraocular pressure (IOP) to ensure the safety of topical atropine. This study aims to identify the optimal machine learning IOP-monitoring module and establish a precise baseline IOP as a clinical safety reference for atropine medication.
Methods:
Data from 1545 eyes of 1171 children receiving atropine for myopia were retrospectively analyzed. Nineteen variables including patient demographics, medical history, refractive error, and IOP measurements were considered. The data were analyzed using a multivariate adaptive regression spline (MARS) model to analyze the impact of different factors on the End IOP.
Results:
The MARS model identified age, baseline IOP, End Spherical, duration of previous atropine treatment, and duration of current atropine treatment as the five most significant factors influencing the End IOP. The outcomes revealed that the baseline IOP had the most significant effect on final IOP, exhibiting a notable knot at 14 mmHg. When the baseline IOP was equal to or exceeded 14 mmHg, there was a positive correlation between atropine use and End IOP, suggesting that atropine may increase the End IOP in children with a baseline IOP greater than 14 mmHg.
Conclusions:
MARS model demonstrates a better ability to capture nonlinearity than classic multiple linear regression for predicting End IOP. It is crucial to acknowledge that administrating atropine may elevate intraocular pressure when the baseline IOP exceeds 14 mmHg. These findings offer valuable insights into factors affecting IOP in children undergoing atropine treatment for myopia, enabling clinicians to make informed decisions regarding treatment options.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Angle Closure Glaucoma: Treatment

